Cargando…

Clinical and biological effects of tumor associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Zhang, Weiwei, Liu, Kejun, Ye, Bin, Hu, Guolin, Zhao, Kelei, Ren, Yazhou, Liang, Weijiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958684/ https://www.ncbi.nlm.nih.gov/pubmed/29805681 http://dx.doi.org/10.3892/ol.2018.8537

Ejemplares similares

Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients
por: Zhang, Weiwei, et al.
Publicado: (2017)

Pretreatment C‐reactive protein/albumin ratio is associated with poor survival in patients with stage IB‐IIA cervical cancer
por: Zhang, Weiwei, et al.
Publicado: (2017)

Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer
por: Zhang, Weiwei, et al.
Publicado: (2017)

Author Correction: Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer
por: Zhang, Weiwei, et al.
Publicado: (2018)

Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients
por: da Silva, Rodrigo Fernandes, et al.
Publicado: (2017)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites
por: den Ouden, Judith E., et al.
Publicado: (2020)

Corrigendum to “Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis”
Publicado: (2020)

Corrigendum to “Effect of Glycyrrhiza on the Diuretic Function of Euphorbia kansui: An Ascites Mouse Model”
por: Lin, Ya, et al.
Publicado: (2018)

Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
por: Kondo, Tomohiro, et al.
Publicado: (2016)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer [Corrigendum]
Publicado: (2021)

Chemotherapy Induces Ovarian Cancer Cell Repopulation Through the Caspase 3-Mediated Arachidonic Acid Metabolic Pathway [Corrigendum]
Publicado: (2022)

[Corrigendum] miR‑1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer
por: Pei, Yuqing, et al.
Publicado: (2023)

Combined antitumor effects of P-5m octapeptide and 5- fluorouracil on a murine model of H22 hepatoma ascites
por: Han, Xiao, et al.
Publicado: (2019)

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
por: Koti, M, et al.
Publicado: (2015)

Corrigendum to “Gamma Radiation-Attenuated Toxoplasma gondii Provokes Apoptosis in Ehrlich Ascites Carcinoma-Bearing Mice Generating Long-Lasting Immunity”
Publicado: (2022)

In situ low-temperature hydrothermal synthesis of LiMn2O4 nanocomposites based on graphene oxide/ carbon nanotubes hydrogel and its capacities
por: Wang, Kelei, et al.
Publicado: (2021)

DRAM-3 modulates autophagy and promotes cell survival in the absence of glucose
por: Mrschtik, M, et al.
Publicado: (2017)

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers
por: Miyamoto, M, et al.
Publicado: (2017)

Corrigendum to “Optimization and Corroboration of the Regulatory Pathway of p42.3 Protein in the Pathogenesis of Gastric Carcinoma”
por: Hao, Yibin, et al.
Publicado: (2015)

Corrigendum to ‘Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis’ [JHEP Reports 3 (2021) 100287]
por: Torp, Nikolaj, et al.
Publicado: (2021)

Corrigendum to “Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients”
por: Zhang, Jue, et al.
Publicado: (2021)

Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment
por: Shi, Gang, et al.
Publicado: (2021)

Total Lymphocyte Count, Neutrophil-Lymphocyte Ratio, and Platelet-Lymphocyte Ratio as Prognostic Factors in Advanced Non-Small Cell Lung Cancer with Chemoradiotherapy [Corrigenudm]
Publicado: (2021)

Chemotherapy of Pneumonias
Publicado: (1979)

Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition
por: Krubasik, D, et al.
Publicado: (2006)

Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites
por: Wefers, Christina, et al.
Publicado: (2019)

Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites
por: Jiao, Jie, et al.
Publicado: (2020)

The Proangiogenic Capabilities of Malignant Ascites Generated by Aggressive Ovarian Tumors
por: Mikuła-Pietrasik, Justyna, et al.
Publicado: (2017)

Corrigendum for “Adverse Outcomes and Economic Burden of Congenital Adrenal Hyperplasia Late Diagnosis in the Newborn Screening Absence”
Publicado: (2021)

Validating genetic risk associations for ovarian cancer through the International Ovarian Cancer Association Consortium
por: Pearce, C L, et al.
Publicado: (2009)

Lapatinib-induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro
por: Liao, Qiuyue, et al.
Publicado: (2021)

Pediatric haematopoiesis and related malignancies
por: Jin, Mingwei, et al.
Publicado: (2021)

Corrigendum to “Cell therapies in ovarian cancer”
Publicado: (2021)

Emerging treatment options for management of malignant ascites in patients with ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2012)

Malignant ascites: a source of therapeutic protein against ovarian cancer?
por: Ribaux, Pascale, et al.
Publicado: (2019)

Corrigendum to “Relationship between leukocyte, neutrophil, lymphocyte, platelet counts, and neutrophil to lymphocyte ratio and polymerase chain reaction positivity”. [Int. Immunopharmacol. 93 (2021) 107390]
por: Kabak, M., et al.
Publicado: (2021)

Corrigendum to “The Protective Effect of N-Acetylcysteine on Ionizing Radiation Induced Ovarian Failure and Loss of Ovarian Reserve in Female Mouse”
por: Gao, Wei, et al.
Publicado: (2021)

WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
por: Zhang, Minghui, et al.
Publicado: (2018)

Is your ice machine really clean? Uncovering the presence of opportunistic pathogens in hospital ice machines – CORRIGENDUM
por: Cazals, Margot, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_12cidiro6d8sa0v7hkto4kg8if